Bio

Mark joined Aquilo Partners in 2021. He brings 20+ years of operating, business development, capital raising and investing experience in life sciences for both private and public biotechnology companies. Prior to joining Aquilo, Mark was Chief Operating Officer at Zyla Lifesciences (sold to Assertio Therapeutics), President and CEO of Corridor Pharmaceuticals (sold to AstraZeneca), and Chief Business Officer of Topaz Pharmaceuticals (acquired by Sanofi Pasteur). He also served as Chief Business Officer of Trevena, Inc. and Vice President of Business Development at GlaxoSmithKline (GSK) where he was responsible for numerous transactions including GSK’s +$1B agreement with Chemocentryx. Earlier in his career, he worked at two venture capital firms, SR One (GSK’s formally wholly owned venture capital firm) and EuclidSR Partners making investments in drug discovery and drug development companies. Mark received a doctorate in biophysics and pharmacology from the University of Cincinnati and completed his post-doctoral fellowship at the University of Pennsylvania. He also received a BS from St. Lawrence University.